|
Extracorporeal Support for Respiratory Insufficiency (ECMO) Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Extracorporeal Support for Respiratory Insufficiency (ECMO) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Extracorporeal Support for Respiratory Insufficiency (ECMO) Clinical research trials and Extracorporeal Support for Respiratory Insufficiency (ECMO) medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Extracorporeal Support for Respiratory Insufficiency (ECMO). Extracorporeal Support for Respiratory Insufficiency (ECMO) Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Extracorporeal Support for Respiratory Insufficiency (ECMO) clinical trial. Participants frequently get the best healthcare available for their Extracorporeal Support for Respiratory Insufficiency (ECMO) condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Extracorporeal Support for Respiratory Insufficiency (ECMO)  Extracorporeal Support for Respiratory Insufficiency (ECMO)
Extracorporeal Support for Respiratory Insufficiency (ECMO)
For Condition: Acute Respiratory Failure,Lung Diseases
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To evaluate indications for the use and efficacy of extracorporeal membrane oxygenators (ECMO's) for the support of patients with potentially reversible acute respiratory failure.
Details: BACKGROUND: The report of the Task Force on Respiratory Diseases identified a clinical syndrome of acute respiratory insufficiency (ARI) and estimated that approximately 60,000 Americans die of ARI yearly. ARI was not precisely defined; indeed, the Task Force realized that pathologists do not recognize ARI. The Task Force pointed out that no diagnostic tests for early detection of ARI exist, that the incidence and prevalence of the disease are not known, and that existing therapy is supportive and nonspecific (diuretics, corticosteroids, etc.). The pathogenesis of the syndrome, the mechanism of interstitial edema, the defenses of the lung against agents causing ARI, and the ultrastructural pathology and natural history of the disease were virtually unknown. The Task Force indicated a need for Respiratory Care Centers with highly trained personnel that could reduce mortality from ARI. This clinical trial grew out of the Task Force report. Nine participating centers defined ARI in clinical and physiological terms and agreed to a prospective randomized study for 3 years to compare treatment of severe ARI by conventional means with treatment by extracorporeal membrane oxygenators. Animal studies have shown that ECMO's can provide one to two weeks' support for the lungs without serious blood damage, in contrast to bubble oxygenators, which allow complete pulmonary bypass for approximately 6 hours, after which severe blood damage occurs at the direct blood-gas interface. If patients with hypoxia secondary to acute reversible lung injury can be supported with ECMO's until the lung lesion heals, improvement in survival rates and avoidance of the hazards of conventional therapy may result. The trial, now completed, was conducted at nine clinical centers in the United States. DESIGN NARRATIVE: Randomized, non-blind, fixed sample; 90 eligible patients were randomly assigned to a group receiving extracorporeal membrane oxygenation plus conventional therapy or to a group receiving conventional therapy.
Eligibility:
Study Type: Interventional, Treatment, Randomized
Minimum Age/Maximum Age: 12 Years/65 Years
Genders: Both
Protocol Entry Criteria: Men and women, ages 12 to 65, not stratified as to ethnic group, who had potentially reversible acute respiratory failure.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertBartlett, , University of California, Irvine
Additional Information:
Study ID Numbers: 200;
Study Start Date: June 1974
Record last reviewed: January 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000562
Other Lung Diseases Studies:
1. Epidemiology of Interstitial Lung Disease
2. Assessment of Lung Inflammation in Patients with Atopic Asthma Using Positron Emission Tomography
3. Inhaled NO for the Prevention of Chronic Lung Disease
4. APPLES: Apnea Positive Pressure Long-Term Efficacy Study
5. Genetics of Asthma and Bronchial Hyperresponsiveness
Related Studies:
Other Lung Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Extracorporeal Support for Respiratory Insufficiency (ECMO)
|
|
|
|
|
|
|
|
